Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

The report – which can be viewed here – highlights the following new medicines: 1) Novo Nordisk's Awiqli (LAI 287; insulin icodec), a long-acting ... $1.6 billion. 4) Eli Lilly and Almirall's ...

Eli Lilly Long-acting GLP-1 analog – incretin mimetic and hypothalamic anorectic agent Launched in 2005 as a treatment for Type 2 diabetes. Currently in Phase II/III trials for the treatment of ...

The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...

According to the FDA, the medication quickly helps to lower mealtime blood sugar spikes to improve control of blood sugar in ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big Pharma is coughing up cash to work with them on radiopharmaceuticals ...